Norge Mining Plc: Publication of Responsible Business Report
1.12.2021 10:00:00 EET | Business Wire | Press release
Norge Mining Plc (“Norge Mining” or the “Company”), the Anglo-Norwegian exploration company developing a world-class resource of Critical Raw Materials in southwest Norway, is pleased to announce publication of its inaugural Responsible Business Report.
The report includes all of the Company’s Environmental, Social and Governance (ESG) information for the year ended 31 December 2020, giving all stakeholders an opportunity to review the Group’s activities and performance.
Norge Mining is committed to sustainable practices and is establishing a range of commitments to align its processes and policies with international guidelines as part of its strategy to build a resilient and robust mining company.
The Company’s Responsible Business Report 2020 can be viewed at this link: https://norgemining.com/wp-content/uploads/2021/11/Norge-Mining_ResponsibleBusinessReport2020_Final_WEB.pdf
The report provides an overview of the Company and a summary of progress at the exciting Bjerkreim Exploration Project, which is focused on the EU Critical Raw Materials vanadium, titanium and phosphate. Resource data published earlier this year gives a total Mineral Resource Estimate at the Bjerkreim project of 1.79 billion tonnes and an Exploration Target of between 2.4 and 4.0 billion tonnes.
John Vergopoulos, Chief Executive Officer of Norge Mining, said:
“As a natural resources company in the early stages of exploration work, we are at the start of an exciting journey towards the mining and processing of critical minerals. We recognise the responsibility that this venture demands and we are determined to embed strong Environmental, Social and Governance principles into our business from the outset and to use innovation to reduce the impact of our activities. We are pleased to publish our inaugural Responsible Business Report and welcome comments from all stakeholders.”
About Norge Mining plc
Norge Mining plc is an Anglo-Norwegian natural resources company focused on mineral exploration in Norway.
The Company’s first Mineral Resource Estimates from the Bjerkreim Exploration Project have confirmed world-class deposits of the EU Critical Raw Materials vanadium, titanium and phosphate. The provenance of these materials is of significant strategic importance for net carbon zero commitments, a key requirement for which is supply chain transparency.
Norge Mining, which owns 61 exploration licences totalling more than 520,000 square kilometres in southwest Norway, is currently conducting a programme of exploration work, building on earlier studies by the Norway Geological Survey (NGU). The Company’s ambition is to become a substantial, sustainable and strategically important exploration and mining business focused on Norway.
Founded in November 2018, the Company is headquartered in the UK and has a 100%-owned Norwegian subsidiary, Norge Mineraler AS.
For further information, please visit www.norgemining.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005942/en/
Contact information
For media enquiries, please contact:
Buchanan Communications
Mark Court / James Husband
+44 (0) 20 7466 5000
norgemining@buchanan.uk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom